Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers Journal Article


Authors: Schweppe, R. E.; Pozdeyev, N.; Pike, L. A.; Korch, C.; Zhou, Q.; Sams, S. B.; Sharma, V.; Pugazhenthi, U.; Raeburn, C.; Albuja-Cruz, M. B.; Reigan, P.; LaBarbera, D. V.; Landa, I.; Knauf, J. A.; Fagin, J. A.; Haugen, B. R.
Article Title: Establishment and characterization of four novel thyroid cancer cell lines and PDX models expressing the RET/PTC1 rearrangement, BRAFV600E, or RASQ61R as drivers
Abstract: Cancer cell lines are critical models to study tumor progression and response to therapy. In 2008, we showed that approximately 50% of thyroid cancer cell lines were redundant or not of thyroid cancer origin. We therefore generated new authenticated thyroid cancer cell lines and patient-derived xenograft (PDX) models using in vitro and feeder cell approaches, and characterized these models in vitro and in vivo. We developed four thyroid cancer cell lines, two derived from 2 different patients with papillary thyroid cancer (PTC) pleural effusions, CUTC5, and CUTC48; one derived from a patient with anaplastic thyroid cancer (ATC), CUTC60; and one derived from a patient with follicular thyroid cancer (FTC), CUTC61. One PDX model (CUTC60-PDX) was also developed. Short tandem repeat (STR) genotyping showed that each cell line and PDX is unique and match the original patient tissue. The CUTC5 and CUTC60 cells harbor the BRAF (V600E) mutation, the CUTC48 cell line expresses the RET/PTC1 rearrangement, and the CUTC61 cells have the HRAS (Q61R) mutation. Moderate to high levels of PAX8 and variable levels of NKX2-1 were detected in each cell line and PDX. The CUTC5 and CUTC60 cell lines form tumors in orthotopic and flank xenograft mouse models. Implications: We have developed the second RET/PTC1-expressing PTC-derived cell line in existence, which is a major advance in studying RET signaling. We have further linked all cell lines to the originating patients, providing a set of novel, authenticated thyroid cancer cell lines and PDX models to study advanced thyroid cancer. © 2019 American Association for Cancer Research.
Journal Title: Molecular Cancer Research
Volume: 17
Issue: 5
ISSN: 1541-7786
Publisher: American Association for Cancer Research  
Date Published: 2019-05-01
Start Page: 1036
End Page: 1048
Language: English
DOI: 10.1158/1541-7786.Mcr-18-1026
PUBMED: 30733375
PROVIDER: scopus
PMCID: PMC6711777
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. James A Fagin
    181 Fagin
  2. Jeffrey A Knauf
    61 Knauf